|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Cara Therapeutics, Inc. (CARA) |
|
|
$0.75 0.00 (-0.48%) as of 4:30 Tue 4/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
49,830,000 |
| Market
Cap: |
37.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.5201 - $4.45 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cara Therapeutics is an early commercial-stage biopharmaceutical company focusing on a new treatment paradigm to improve the lives of patients suffering from pruritus. Co.'s KORSUVA injection is an FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease, in adults undergoing hemodialysis. Co. is developing an Oral KORSUVA (difelikefalin) formulation for the treatment of pruritus in patients with atopic dermatitis, and non-dialysis-dependent chronic kidney disease. Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis, and in notalgia paresthetica patients with moderate-to-severe pruritus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
58,482 |
58,482 |
74,857 |
179,408 |
| Total Sell Value |
$37,219 |
$37,219 |
$96,243 |
$919,932 |
| Total People Sold |
3 |
3 |
4 |
8 |
| Total Sell Transactions |
7 |
7 |
12 |
31 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Vifor Fresenius Medical Care Renal Pharma Ltd. |
10% Owner |
– – • |
2021-10-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,396,770 |
|
-14% |
|
| Chalmers Derek T |
President & CEO |
• • – |
2021-09-07 |
4 |
S |
$15.47 |
$309,400 |
D/D |
(20,000) |
991,405 |
|
26% |
|
| Menzaghi Frederique Ph.d. |
Chief Scientific Off,SVP-R&D |
• – – |
2021-08-30 |
4 |
AS |
$14.20 |
$54,627 |
D/D |
(3,847) |
141,072 |
|
-18% |
|
| Chalmers Derek T |
President & CEO |
• • – |
2021-08-30 |
4 |
AS |
$14.20 |
$119,848 |
D/D |
(8,440) |
1,011,405 |
|
-18% |
|
| Goncalves Joana |
Chief Medical Officer |
• – – |
2021-08-30 |
4 |
AS |
$14.20 |
$29,962 |
D/D |
(2,110) |
47,900 |
|
-18% |
|
| Terrillion Scott |
Secy; Chief Compliance & G.C. |
• – – |
2021-08-30 |
4 |
AS |
$14.20 |
$24,978 |
D/D |
(1,759) |
70,917 |
|
-18% |
|
| Reilly Thomas Charles |
Chief Financial Officer |
• – – |
2021-08-30 |
4 |
AS |
$14.20 |
$28,144 |
D/D |
(1,982) |
3,352 |
|
-18% |
|
| Terrillion Scott |
Secy; Chief Compliance & G.C. |
• – – |
2021-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
5,334 |
72,676 |
|
- |
|
| Goncalves Joana |
Chief Medical Officer |
• – – |
2021-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,400 |
50,010 |
|
- |
|
| Reilly Thomas Charles |
Chief Financial Officer |
• – – |
2021-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
5,334 |
5,334 |
|
- |
|
| Chalmers Derek T |
President & CEO |
• • – |
2021-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
17,334 |
1,019,845 |
|
- |
|
| Menzaghi Frederique Ph.d. |
Chief Scientific Off,SVP-R&D |
• – – |
2021-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
9,600 |
144,919 |
|
- |
|
| Posner Christopher |
Director |
– • – |
2021-06-07 |
4 |
AS |
$13.04 |
$30,044 |
D/D |
(2,304) |
16,096 |
|
-1% |
|
| Vogelbaum Martin |
Director |
– • – |
2021-06-07 |
4 |
AS |
$13.05 |
$112,752 |
D/D |
(8,640) |
20,160 |
|
-1% |
|
| Ives Jeffrey L. |
Director |
– • – |
2021-06-07 |
4 |
AS |
$13.05 |
$32,886 |
D/D |
(2,520) |
15,380 |
|
-1% |
|
| Posner Christopher |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
7,200 |
18,400 |
|
- |
|
| Bains Harrison M Jr |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
7,200 |
20,400 |
|
- |
|
| Shiff Susan Ph.d. |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
7,200 |
7,200 |
|
- |
|
| Vogelbaum Martin |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
14,400 |
28,800 |
|
- |
|
| Ives Jeffrey L. |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
7,200 |
17,900 |
|
- |
|
| Goncalves Joana |
Chief Medical Officer |
• – – |
2021-04-21 |
4 |
AS |
$27.63 |
$82,890 |
D/D |
(3,000) |
43,610 |
|
-47% |
|
| Terrillion Scott |
Secy; Chief Compliance & G.C. |
• – – |
2021-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
67,342 |
|
- |
|
| Goncalves Joana |
Chief Medical Officer |
• – – |
2021-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
46,610 |
|
- |
|
| Menzaghi Frederique Ph.d. |
Chief Scientific Off,SVP-R&D |
• – – |
2021-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
135,319 |
|
- |
|
| Chalmers Derek T |
President & CEO |
• • – |
2021-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
52,000 |
1,002,511 |
|
- |
|
116 Records found
|
|
Page 1 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
